专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005094305A2 COMBINATION THERAPY FOR WEIGHT MANAGEMENT 审中-公开
标题翻译：重量管理的组合治疗
公开(公告)号：WO2005094305A2
公开(公告)日：2005-10-13
申请号：PCT/US2005010325
申请日：2005-03-28
申请人： NEUROGEN CORP , KRAUSE JAMES , DOLLER DARIO , BERETTA ELENA , RAJACHANDRAN LAVANYA , BRODBECK ROBBIN
发明人： KRAUSE JAMES , DOLLER DARIO , BERETTA ELENA , RAJACHANDRAN LAVANYA , BRODBECK ROBBIN
IPC分类号： A61K31/38 , A61K31/397 , A61K31/40 , A61K31/415 , A61K31/445 , A61K31/454 , A61K31/4965 , A61K31/535 , A61K31/5377 , A61K31/55 , A61K45/06
CPC分类号： A61K45/06 , A61K31/454 , A61K31/5377 , A61K2300/00
摘要： Compositions and methods are provided for weight management. The compositions generally comprise a MCHR antagonist, either in combination with a CB1 antagonist or formulated for coadministration with a CB1 antagonist. Certain methods involve coadministering a MCHR antagonist and a CB1 antagonist to a patient.
摘要翻译：提供组合和方法用于体重管理。组合物通常包含MCHR拮抗剂，与CB1拮抗剂组合或配制用于与CB1拮抗剂共同给药。某些方法涉及向患者共同施用MCHR拮抗剂和CB1拮抗剂。

2. 发明申请

WO2004028453A2 METHODS FOR PREVENTING AND TREATING OBESITY IN PATIENTS WITH MC4 RECEPTOR MUTATIONS 审中-公开
标题翻译：用于预防和治疗患有MC4受体突变的患者的肥胖的方法
公开(公告)号：WO2004028453A2
公开(公告)日：2004-04-08
申请号：PCT/US0329916
申请日：2003-09-23
申请人： NEUROGEN CORP , RAJACHANDRAN LAVANYA , BERETTA ELENA , KRAUSE JAMES
发明人： RAJACHANDRAN LAVANYA , BERETTA ELENA , KRAUSE JAMES
IPC分类号： A61K31/00 , A61K45/06 , A61K
CPC分类号： C12Q1/6883 , A61K31/00 , A61K45/06 , C12Q2600/156
摘要： Methods are provided for treating health conditions associated with altered MC4 receptor activity with melanin concentrating hormone receptor antagonists. Such compounds may be used, for example, to treat or prevent obesity and/or overeating, and to reduce body mass index, in patients carrying one or more MC4 receptor mutations.
摘要翻译：提供了用于治疗与由黑色素浓缩激素受体拮抗剂改变的MC4受体活性相关的健康状况的方法。在携带一种或多种MC4受体突变的患者中，这样的化合物可用于例如治疗或预防肥胖和/或暴饮暴食并减少体重指数。

3. 发明申请

WO0155103A3 CHIMERIC NEUROPEPTIDE Y RECEPTORS 审中-公开
标题翻译：嵌合神经肽Y受体
公开(公告)号：WO0155103A3
公开(公告)日：2001-12-13
申请号：PCT/US0102804
申请日：2001-01-29
申请人： NEUROGEN CORP
发明人： BENNETT MICHELE , BRODBECK ROBBIN , KRAUSE JAMES
IPC分类号： C12N15/09 , A61K45/00 , A61P9/00 , A61P25/00 , A61P25/22 , C07K14/705 , C07K19/00 , C12N5/10 , C12Q1/02 , C12R1/91 , C07H21/04 , C12N15/63 , C12N15/85 , C12N15/86 , C12P21/06 , G01N33/53 , C07K5/100
CPC分类号： C07K14/70571
摘要： Novel chimeric G-protein coupled receptors are provided as isolated polypeptides, membrane preparations containing such chimeric receptors, nucleic acids encoding such chimeric receptors, and cells expressing such receptors. The chimeric receptors are NPY5 receptors with most or all of either one or both of the third cytoplasmic loop domain or the C-terminal intracellular domain of NPY5 replaced with the corresponding region(s) of another NPY receptor, preferably an NPY1 receptor.
摘要翻译：提供了新的嵌合G蛋白偶联受体作为分离的多肽，含有此类嵌合受体的膜制剂，编码此类嵌合受体的核酸和表达此类受体的细胞。嵌合受体是NPY5受体，其中大部分或全部第三胞质环结构域之一或两者或NPY5的C末端胞内结构域被另一NPY受体的对应区域（优选NPY1受体）取代。

4. 发明公开

EP1490044A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS 审中-公开
标题翻译：联合治疗条件致病炎性成分的治疗
公开(公告)号：EP1490044A4
公开(公告)日：2008-04-16
申请号：EP03716867
申请日：2003-03-27
申请人： NEUROGEN CORP
发明人： KRAUSE JAMES
IPC分类号： A61K45/00 , A61K31/16 , A61K31/166 , A61K31/4164 , A61K31/417 , A61K31/4178 , A61K31/42 , A61K31/422 , A61K31/426 , A61K31/427 , A61K31/47 , A61K31/4709 , A61K31/472 , A61K31/498 , A61K31/519 , A61K31/56 , A61K31/57 , A61K31/60 , A61K33/24 , A61K45/06 , A61P1/04 , A61P3/06 , A61P3/14 , A61P7/02 , A61P7/08 , A61P7/10 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P17/02 , A61P17/06 , A61P19/02 , A61P21/04 , A61P25/00 , A61P25/28 , A61P29/00 , A61P31/00 , A61P31/04 , A61P37/06 , A61P43/00 , A61K31/19 , A61K31/415 , A61K31/445
CPC分类号： A61K31/4178 , A61K31/16 , A61K31/4164 , A61K31/426 , A61K31/427 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： Compositions and methods for treating diseases that are associated with inflammation are provided. Such diseases include arthritis (particularly rheumatoid arthritis) and other autoimmune disorders, asthma, cardio- and cerebrovascular disease, burns, psoriasis, reperfusion injury, and traumatic CNS and spinal cord injury. The compositions generally comprise at least one C5a antagonist and at least one C5a receptor-inactive therapeutic agent. The methods involve co-administration of at least one C5a antagonist and at least one C5a receptor-inactive therapeutic agent to a patient. The C5a antagonist and C5a receptor-inactive therapeutic agent may be present within the same composition, or may be administered separately to the patient.

5. 发明公开

EP1263768A4 CHIMERIC NEUROPEPTIDE Y RECEPTORS 审中-公开
标题翻译：嵌合受体神经肽Y
公开(公告)号：EP1263768A4
公开(公告)日：2004-05-12
申请号：EP01914335
申请日：2001-01-29
申请人： NEUROGEN CORP
发明人： BENNETT MICHELE , BRODBECK ROBBIN , KRAUSE JAMES
IPC分类号： C12N15/09 , A61K45/00 , A61P9/00 , A61P25/00 , A61P25/22 , C07K14/705 , C07K19/00 , C12N5/10 , C12Q1/02 , C12R1/91 , C07H21/04 , C12P21/00
CPC分类号： C07K14/70571

6. 发明公开

EP1729762A4 COMBINATION THERAPY FOR WEIGHT MANAGEMENT 审中-公开
标题翻译：联合治疗控制体重
公开(公告)号：EP1729762A4
公开(公告)日：2007-12-19
申请号：EP05743960
申请日：2005-03-28
申请人： NEUROGEN CORP
发明人： KRAUSE JAMES , DOLLER DARIO , BERETTA ELENA , RAJACHANDRAN LAVANYA , BRODBECK ROBBIN
IPC分类号： A61K31/454 , A61K31/38 , A61K31/397 , A61K31/40 , A61K31/415 , A61K31/445 , A61K31/4965 , A61K31/535 , A61K31/5377 , A61K31/55 , A61K45/06 , A61P3/04 , G01N33/15
CPC分类号： A61K45/06 , A61K31/454 , A61K31/5377 , A61K2300/00

7. 发明申请

WO2005013041A3 SYSTEM AND METHOD FOR CONTROLLING MARKETS DURING A STOP LOSS TRIGGER 审中-公开
标题翻译：用于在停止失败触发器期间控制市场的系统和方法
公开(公告)号：WO2005013041A3
公开(公告)日：2005-10-20
申请号：PCT/US2004022661
申请日：2004-07-14
申请人： CHICAGO MERCANTIL EXCHANGE INC , FARRELL JAMES , KRAUSE JAMES , CHADID MAZEN
发明人： FARRELL JAMES , KRAUSE JAMES , CHADID MAZEN
IPC分类号： G06F20060101 , G06F17/16 , G06Q40/00
CPC分类号： G06Q40/04 , G06Q40/00 , G06Q40/06
摘要： A system mitigates the effects of a market spike caused by the triggering and the election of a conditional order in an automated matching system. The system includes evaluation logic, delay logic, pricing logic and timing logic. The evaluation logic monitors conditional orders submitted to a trading engine and is configured to compare a price of an order to a first predefined price range. The delay logic delays matching of the orders submitted to the trading engine when the price of the orders lie outside of the first predefined price range. The pricing logic derives an opening price to be used by the trading engine. The timing logic measures a time interval used to delay a matching of the orders until the opening price is within a predefined price range up to a maximum delay time set by a control center. A method of mitigating the effect of a market spike caused by the triggering and the election of a conditional order includes monitoring conditional orders submitted to the trading engine.
摘要翻译：系统减轻了自动匹配系统中触发和选择条件订单引起的市场飙升的影响。该系统包括评估逻辑，延迟逻辑，定价逻辑和定时逻辑。评估逻辑监视提交给交易引擎的条件订单，并且被配置为将订单的价格与第一预定价格范围进行比较。当订单的价格在第一预定价格范围之外时，延迟逻辑延迟提交给交易引擎的订单的匹配。定价逻辑得出交易引擎使用的开盘价。定时逻辑测量用于延迟订单匹配的时间间隔，直到开盘价在预定价格范围内，直到由控制中心设置的最大延迟时间为止。一种减轻由触发和选择条件订单引起的市场飙升效应的方法包括监控提交给交易引擎的有条件订单。

8. 发明专利

AU2003275150A8 Methods for preventing and treating obesity in patients with mc4 receptor mutations 未知
公开(公告)号：AU2003275150A8
公开(公告)日：2004-04-19
申请号：AU2003275150
申请日：2003-09-23
申请人： NEUROGEN CORP
发明人： KRAUSE JAMES , RAJACHANDRAN LAVANYA , BERETTA ELENA
IPC分类号： A61K31/00 , A61K45/06 , A01N61/00 , C12N15/00
摘要： Methods are provided for treating health conditions associated with altered MC4 receptor activity with melanin concentrating hormone receptor antagonists. Such compounds may be used, for example, to treat or prevent obesity and/or overeating, and to reduce body mass index, in patients carrying one or more MC4 receptor mutations.

9. 发明专利

AU3973101A Chimeric neuropeptide y receptors 未知
公开(公告)号：AU3973101A
公开(公告)日：2001-08-07
申请号：AU3973101
申请日：2001-01-29
申请人： NEUROGEN CORP
发明人： BENNETT MICHELE , BRODBECK ROBBIN , KRAUSE JAMES
IPC分类号： C12N15/09 , A61K45/00 , A61P9/00 , A61P25/00 , A61P25/22 , C07K14/705 , C07K19/00 , C12N5/10 , C12Q1/02 , C12R1/91
摘要： Novel chimeric G-protein coupled receptors are provided as isolated polypeptides, membrane preparations containing such chimeric receptors, nucleic acids encoding such chimeric receptors, and cells expressing such receptors. The chimeric receptors are NPY5 receptors with most or all of either one or both of the third cytoplasmic loop domain or the C-terminal intracellular domain of NPY5 replaced with the corresponding region(s) of another NPY receptor, preferably an NPY1 receptor.

10. 发明专利

CA2557998A1 COMBINATION THERAPY FOR WEIGHT MANAGEMENT 未知
公开(公告)号：CA2557998A1
公开(公告)日：2005-10-13
申请号：CA2557998
申请日：2005-03-28
申请人： NEUROGEN CORP
发明人： DOLLER DARIO , KRAUSE JAMES , BERETTA ELENA , RAJACHANDRAN LAVANYA , BRODBECK ROBBIN
IPC分类号： A61K31/397 , A61K31/38 , A61K31/40 , A61K31/415 , A61K31/445 , A61K31/454 , A61K31/4965 , A61K31/535 , A61K31/5377 , A61K31/55 , A61K45/06
摘要： Compositions and methods are provided for weight management. The compositions generally comprise a MCHR antagonist, either in combination with a CB1 antagonist or formulated for coadministration with a CB1 antagonist. Certain methods involve coadministering a MCHR antagonist and a CB1 antagonist to a patient.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式